SCHEMBL246339

SCHEMBL246339

O=Nc1ccc([AsH2])cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL234461 0.83 ALDH1A1 (0.58) —
SCHEMBL24385153 0.73 ALDH1A1 (0.50) —
SCHEMBL10887099 0.73 ALDH1A1 (0.50) —
SCHEMBL712641 0.71 — —
SCHEMBL107699 0.69 — —
SCHEMBL941642 0.69 — —
SCHEMBL13181134 0.69 — —
SCHEMBL25191034 0.69 — —
SCHEMBL9139528 0.69 — —
SCHEMBL10053525 0.69 ALDH1A1 (0.46) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1156817-B1 CONTROLLING PROTEIN LEVELS IN EUCARYOTIC ORGANISMS WELLSTAT BIOCATALYSIS LLC (US) 2008-08-27 — — EP claimed
EP-3676282-B1 ANTI-CANCER AGENT UNIV WOLLONGONG (AU) 2024-11-06 — — EP disclosed
CN-111344298-B Anticancer agent 伍伦贡大学 2024-05-28 — — CN disclosed
US-11819489-B2 Anti-cancer agent comprising a tumour homing peptide having arsenic bonded to cysteine residues UNIVERSITY OF WOLLONGONG (AU) 2023-11-21 — — US disclosed
CN-113173952-B Ortho-dithiol reactive therapeutic probe for drug release monitoring and preparation 济南大学 2022-05-24 — — CN disclosed
CN-113173952-A Ortho-dithiol reactive therapeutic probe for drug release monitoring and preparation 济南大学 2021-07-27 — — CN disclosed
US-20210205259-A1 ANTI-CANCER AGENT UNIVERSITY OF WOLLONGONG (AU) 2021-07-08 — — US disclosed
CN-106892515-B Method for treating high-concentration organic arsenic wastewater and recycling arsenic 中国科学院生态环境研究中心 2021-03-02 — — CN disclosed
EP-3676282-A1 ANTI-CANCER AGENT University of Wollongong (AU) 2020-07-08 — — EP disclosed
CN-111344298-A Anticancer agent 伍伦贡大学 2020-06-26 — — CN disclosed
EP-0946556-A4 COMBINATORIAL PROCESS FOR PREPARING HYDROFUROQUINOLINE LIBRARIES LILLY CO ELI (US) 2001-07-04 — — EP disclosed
EP-1071958-A1 METHODS FOR SUBSTRATE-LIGAND INTERACTION SCREENING Arcaris, Inc. (US) 2001-01-31 — — EP disclosed
WO-2000049417-A1 METHODS FOR SUBSTRATE-LIGAND INTERACTION SCREENING ARCARIS, INC. (US) 2000-08-24 — — WO disclosed
WO-2000047220-A1 CONTROLLING PROTEIN LEVELS IN EUCARYOTIC ORGANISMS PROTEINIX, INC. (US) 2000-08-17 — — WO disclosed
EP-0946556-A1 COMBINATORIAL PROCESS FOR PREPARING HYDROFUROQUINOLINE LIBRARIES ELI LILLY AND COMPANY (US) 1999-10-06 — — EP disclosed
WO-1998027093-A1 COMBINATORIAL PROCESS FOR PREPARING HYDROFUROQUINOLINE LIBRARIES ELI LILLY AND COMPANY (US) 1998-06-25 — — WO disclosed
US-5252466-A Hybrids BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION (US) 1993-10-12 — — US disclosed
EP-0472658-A4 FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION BIOTECHNOLOGY RES & DEV (US) 1992-08-26 — — EP disclosed
EP-0472658-A1 FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION INCORPORATED (US) 1992-03-04 — — EP disclosed
WO-1990014431-A1 FUSION PROTEINS HAVING AN IN VIVO POST-TRANSLATIONAL MODIFICATION SITE AND METHODS OF MANUFACTURE AND PURIFICATION BIOTECHNOLOGY RESEARCH AND DEVELOPMENT CORPORATION (US) 1990-11-29 — — WO disclosed
Send feedback